Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.41 |
| ▸ | GLP1R | P43220 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 7/20 | 0.39 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25373333 | 1.00 | ACSS2 (0.42) | ACSS2AGTR1AGTR2GLP1RLMNA | |
| SCHEMBL26541102 | 0.91 | LMNA (0.38) | ACSS2AGTR1AGTR2GLP1RLMNA | |
| SCHEMBL26237230 | 0.90 | ACSS2 (0.46) | ACSS2LMNA | |
| SCHEMBL31202954 | 0.90 | ACSS2 (0.46) | ACSS2LMNA | |
| SCHEMBL27153108 | 0.87 | ACSS2 (0.47) | ACSS2AGTR1AGTR2LMNALGALS8 | |
| SCHEMBL27478696 | 0.79 | ACSS2 (0.43) | ACSS2LMNA | |
| SCHEMBL27478697 | 0.79 | ACSS2 (0.43) | ACSS2LMNA | |
| SCHEMBL30474209 | 0.79 | TLR7 (0.48) | ACSS2LMNA | |
| SCHEMBL31143264 | 0.75 | TP53 (0.50) | ACSS2 | |
| SCHEMBL27111194 | 0.75 | AGTR1 (0.42) | ACSS2AGTR1AGTR2GLP1RHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322758-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023164050-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322758-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | ACSS2 1527/4885AGTR1 143/4885AGTR2 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.